Abstract
Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1+, CD68+ and CD206+ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1+ macrophage infiltration.
Original language | English |
---|---|
Pages (from-to) | 985-989 |
Number of pages | 5 |
Journal | Internal Medicine |
Volume | 58 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- FGFR
- Immune checkpoint inhibitor
- PD-1
- PD-L1
- Pulmonary pleomorphic carcinoma
ASJC Scopus subject areas
- Internal Medicine